Mainz Financial Statements From 2010 to 2024

MYNZ Stock  USD 7.32  0.40  5.78%   
Mainz Biomed financial statements provide useful quarterly and yearly information to potential Mainz Biomed BV investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Mainz Biomed financial statements helps investors assess Mainz Biomed's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Mainz Biomed's valuation are summarized below:
Mainz Biomed BV does not presently have any fundamental ratios for analysis.
Check Mainz Biomed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mainz Biomed's main balance sheet or income statement drivers, such as , as well as many indicators such as . Mainz financial statements analysis is a perfect complement when working with Mainz Biomed Valuation or Volatility modules.
  
Check out the analysis of Mainz Biomed Correlation against competitors.

Mainz Biomed BV Company Return On Asset Analysis

Mainz Biomed's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Mainz Biomed Return On Asset

    
  -0.99  
Most of Mainz Biomed's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mainz Biomed BV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Based on the latest financial disclosure, Mainz Biomed BV has a Return On Asset of -0.9924. This is 88.66% lower than that of the Biotechnology sector and 86.82% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.

Mainz Biomed BV Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Mainz Biomed's current stock value. Our valuation model uses many indicators to compare Mainz Biomed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mainz Biomed competition to find correlations between indicators driving Mainz Biomed's intrinsic value. More Info.
Mainz Biomed BV is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mainz Biomed's earnings, one of the primary drivers of an investment's value.

About Mainz Biomed Financial Statements

Mainz Biomed investors use historical fundamental indicators, such as Mainz Biomed's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Mainz Biomed. Please read more on our technical analysis and fundamental analysis pages.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic and research use only tests for clinical diagnostics in human genetics. The company was founded in 2008 and is based in Mainz, Germany. Mainz Biomed is traded on NASDAQ Exchange in the United States.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Mainz Stock Analysis

When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.